Last checked at 
(Alliance News) - Hutchison China MediTech Ltd said Monday that the independent Data Monitoring Committee in China has recommended an early closure of the surufatinib phase III SANET-p study, as pre-defined primary endpoint of progression free survival has already been met.
SANET-p is a phase III study in China of surufatinib in patients with advanced pancreatic neuroendocrine tumor for whom there is no effective therapy.
Following the early success of the study, the company said it now plans to arrange a meeting with the China National Medical Products Administration to discuss the preparation of the New Drug Application for surufatinib.
Hutchison China said it is currently building an oncology-focused sales and marketing team to launch surufatinib if approved in China.
Christian Hogg, chief executive officer, said: "Following surufatinib's New Drug Application submission for the treatment of non-pancreatic neuroendocrine tumors, these positive results for pancreatic neuroendocrine tumors reinforce that surufatinib has the unique opportunity to address all advanced neuroendocrine tumors."
Hutchinson China shares were up 2.2% in London at 460.00 pence each on Monday.
By Loreta Juodagalvyte; loretajuodagalvyte@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
